Laniquidar

Laniquidar
Clinical data
ATC code	none;
Identifiers
	IUPAC name methyl 11-(1-{2-[4-(quinolin-2-ylmethoxy)phenyl]ethyl}piperidin-4-ylidene)-6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate;
CAS Number	197509-46-9;
PubChem CID	6450806;
ChemSpider	4953357;
UNII	K3FRN4DDOY;
CompTox Dashboard (EPA)	DTXSID10173436 ;
Chemical and physical data
Formula	C37H36N4O3
Molar mass	584.720 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC(=O)C1=CN=C2N1CCC3=CC=CC=C3C2=C4CCN(CC4)CCC5=CC=C(C=C5)OCC6=NC7=CC=CC=C7C=C6;
	InChI InChI=1S/C37H36N4O3/c1-43-37(42)34-24-38-36-35(32-8-4-2-6-27(32)19-23-41(34)36)29-17-21-40(22-18-29)20-16-26-10-14-31(15-11-26)44-25-30-13-12-28-7-3-5-9-33(28)39-30/h2-15,24H,16-23,25H2,1H3; Key:TULGGJGJQXESOO-UHFFFAOYSA-N;
	(verify)

Laniquidar (INN) is a P-glycoprotein inhibitor undergoing clinical studies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).^[1]

References

^ Ross DD (December 2004). "Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome". Best Practice & Research. Clinical Haematology. 17 (4): 641–51. doi:10.1016/j.beha.2004.08.014. PMID 15494300.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.